.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Teva
Deloitte
Julphar
Healthtrust
Accenture
Covington
Citi
Fuji
Johnson and Johnson

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,544,364

« Back to Dashboard

Which drugs does patent 7,544,364 protect, and when does it expire?


Patent 7,544,364 protects VIBATIV and is included in one NDA.

This patent has eighty-eight patent family members in thirty-four countries.

Summary for Patent: 7,544,364

Title:Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Abstract:Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.
Inventor(s): Judice; J. Kevin (El Granada, CA), Shaw; Jeng-Pyng (Saratoga, CA), Mu; YongQi (Los Altos, CA), Conner; Michael W. (Half Moon Bay, CA), Pace; John L. (San Anselmo, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Application Number:11/410,597
Patent Claim Types:
see list of patent claims
Composition; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Theravance BiopharmaVIBATIVtelavancin hydrochloridePOWDER;IV (INFUSION)022110-001Sep 11, 2009DISCNYesNo► Subscribe► Subscribe► SubscribeY
Theravance BiopharmaVIBATIVtelavancin hydrochloridePOWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,544,364

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,265,086Glycopeptide carboxy-saccharide derivatives► Subscribe
7,208,471Glycopeptide phosphonate derivatives► Subscribe
6,872,701 Glycopeptide phosphonate derivatives► Subscribe
7,700,550Glycopeptide phosphonate derivatives► Subscribe
7,074,760Polyacid glycopeptide derivatives► Subscribe
7,008,923Glycopeptide phosphonate derivatives► Subscribe
6,620,781 Glycopeptide carboxy-saccharide derivatives► Subscribe
8,158,580Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin► Subscribe
8,859,506Glycopeptide phosphonate derivatives► Subscribe
6,872,804 Glycopeptide disulfide and thioester derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,544,364

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea100768488► Subscribe
South Korea20030032970► Subscribe
Japan2008222718► Subscribe
Japan2008231109► Subscribe
Japan2003531869► Subscribe
Japan4870314► Subscribe
Japan2007045842► Subscribe
Japan4713810► Subscribe
Japan2003531917► Subscribe
Japan2004501161► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Boehringer Ingelheim
Cantor Fitzgerald
Harvard Business School
Cipla
Chubb
Teva
Express Scripts
Queensland Health
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot